Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.

Oncology reports - 1 Apr 2021

Uranowska Karolina, Kalic Tanja, Valtsanidis Veronika, Kitzwögerer Melitta, Breiteneder Heimo, Hafner Christine

Abstract excerpt

Chondroitin sulfate proteoglycan 4 (CSPG4) is a multifunctional transmembrane proteoglycan involved in spreading, migration and invasion of melanoma. In addition to the activating BRAF V600E mutation, CSPG4 was shown to promote MAPK signaling by mediating the growth‑factor induced activation of receptor tyrosine kinases. However, it remains elusive which factors regulate CSPG4 expression. Therefore, the aim of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Chondroitin Sulfate Proteoglycans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Down-Regulation

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 33649790
DOI: 10.3892/or.2021.7965
PMCID: PMC7876987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.PMID 33649790Read ↗

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.Semantic proximity Read ↗

Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell CarcinomaSemantic proximity Read ↗

Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal TransitionSemantic proximity Read ↗

Exogenous Recombinant N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B; ARSB) Inhibits Progression of B16F10 Cutaneous Melanomas and Modulates Cell SignalingSemantic proximity Read ↗

A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.Semantic proximity Read ↗

Dual Specificity Phosphatase 1 (DUSP1) Provides Mechanistic Link Between Melanoma Cellular Plasticity and Drug ResistanceSemantic proximity Read ↗

Identification and functional analysis of SOX10 phosphorylation sites in melanomaSemantic proximity Read ↗

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFSemantic proximity Read ↗

Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas.Semantic proximity Read ↗

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.Semantic proximity Read ↗

BRAFV600E dictates cell survival via c-Myc-dependent induction of Skp2 in human melanoma.Semantic proximity Read ↗

P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.